Artelo Biosciences, Inc. (ARTL) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.1x

Market Cap

$3.24M

MomentumView details →

1D Return

−4.98%

YTD Return

−44.44%

RSI (14)

37.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.1x

Market Cap

$3.24M

RSI (14)

37.8

MomentumView details →

1D Return

−4.98%

YTD Return

−44.44%

SummaryUpdated Jun 1, 2026

Artelo Biosciences, Inc. (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Solana Beach, California. Originally incorporated as Reactive Medical, Inc., the company rebranded to Artelo Biosciences in April 2017 and went public in June 2019. Artelo specializes in developing therapeutic treatments that target the endocannabinoid system, a complex cell-signaling system in the human body that plays a role in regulating various physiological processes including appetite, pain sensation, mood, and immune function.

Ask drillr about Artelo Biosciences, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−253.57%

ROA (TTM)

−196.18%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

−89.91%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−15.77%

EarningsView details →

EPS (Actual)

−$0.89

EPS Surprise

−23.61%

Beats (12Q)

3/12

Next Q EPS Est

−$7.02

Avg Surprise (4Q)

−244.61%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.00x

Quick Ratio

3.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−12.67M

Op. CF (TTM)

−12.63M

Next earningsNov 17, 2026 →

Latest newsMore news →

Artelo Biosciences announced that the Japanese Patent Office issued a notice of allowance and Decision to Grant for its patent application covering the intended commercial formulation of ART27.13.16d ago

Artelo Biosciences announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering the intended commercial formulation of ART27.13, expected to extend patent protection through 2041.19d ago

Similar companies

60 Degrees Pharmaceuticals, Inc.SXTP Curis, Inc.CRIS Aptevo Therapeutics Inc.APVO Jaguar Health, Inc.JAGX SciSparc Ltd.SPRC Affimed N.V.AFMD Find similar companies →

Latest newsMore news →

Artelo Biosciences announced that the Japanese Patent Office issued a notice of allowance and Decision to Grant for its patent application covering the intended commercial formulation of ART27.13.16d ago Artelo Biosciences announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering the intended commercial formulation of ART27.13, expected to extend patent protection through 2041.19d ago